119 related articles for article (PubMed ID: 24549123)
1. Screening urged for hepatitis C but drug costs are prohibitive.
Fralick M
CMAJ; 2014 Mar; 186(5):329. PubMed ID: 24549123
[No Abstract] [Full Text] [Related]
2. Medicine. Hepatitis C can be cured globally, but at what cost?
Hill A; Cooke G
Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
[No Abstract] [Full Text] [Related]
3. Dare to refuse the exorbitant price of Sovaldi!
Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
[No Abstract] [Full Text] [Related]
4. China rejects patent on hepatitis C drug sofosbuvir.
Kmietowicz Z
BMJ; 2015 Jun; 350():h3429. PubMed ID: 26105994
[No Abstract] [Full Text] [Related]
5. Guideline: New HCV drugs should go to sickest patients.
Kuehn BM
JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
[No Abstract] [Full Text] [Related]
6. WHO issues guidelines on HCV amid drug cost controversy.
Slomski A
JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C drugs not reaching poor.
Callaway E
Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042
[No Abstract] [Full Text] [Related]
9. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
Phelan M; Cook C
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S5. PubMed ID: 25253373
[No Abstract] [Full Text] [Related]
10. New expensive treatments for hepatitis C infection.
Brennan T; Shrank W
JAMA; 2014 Aug; 312(6):593-4. PubMed ID: 25038617
[No Abstract] [Full Text] [Related]
11. Elimination on the agenda for hepatitis C.
Burki T
Lancet Infect Dis; 2014 Jun; 14(6):452-3. PubMed ID: 24971446
[No Abstract] [Full Text] [Related]
12. US health insurers say Gilead hepatitis C drug too costly.
Clin Infect Dis; 2014 Jul; 59(2):i-ii. PubMed ID: 25105185
[No Abstract] [Full Text] [Related]
13. [Is more expensive always better?].
Drenth JP
Ned Tijdschr Geneeskd; 2014; 159():A8556. PubMed ID: 25534272
[TBL] [Abstract][Full Text] [Related]
14. The price of good health.
Nat Med; 2014 Apr; 20(4):319. PubMed ID: 24710362
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
Cohen J
Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
[No Abstract] [Full Text] [Related]
16. Gilead injects own generics into shrinking HCV drug market.
Morrison C
Nat Biotechnol; 2018 Nov; 36(11):1030. PubMed ID: 30412188
[No Abstract] [Full Text] [Related]
17. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
18. Campaigners challenge patent applications for hepatitis C drug in five countries.
Bagcchi S
BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985
[No Abstract] [Full Text] [Related]
19. Sovaldi makes blockbuster history, ignites drug pricing unrest.
Senior M
Nat Biotechnol; 2014 Jun; 32(6):501-2. PubMed ID: 24911474
[No Abstract] [Full Text] [Related]
20. Sovaldi dilemma likely to get worse.
Carroll J
Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
[No Abstract] [Full Text] [Related]
[Next] [New Search]
